A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
Completed · Phase 2
Conditions studied: Hepatocellular Carinoma
In brief
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in five weekly IV infusions.
Key facts
- Study ID
- NCT01636284
- Run by
- Jennerex Biotherapeutics
- People needed
- 16
- Starts
- 2012-06-01
- Expected to finish
- 2013-06-01
- Last updated by the study team
- 2021-01-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Scottsdale, Arizona, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
- Pusan National University Hospital — Pusan, South Korea
- Pusan National University Yangsan Hospital — Yangsan, South Korea
- University Clinic of Navarra — Pamplona, Navarre, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.